Animal Study #1 (GLP-1-A26-1) began dosing on June 10, 2026, as planned, and is expected to yield results by early September after testing 11 novel DHT-semaglutide and DHT-CBD formulations in Sprague-Dawley rats with multiple pharmacokinetic and brain biodistribution timepoints. Lexaria filed three new patent applications for its SNAC alternative and on June 11 received Australian patent #2023302884 extending its pharmaceutical composition IP through April 25, 2043.
The GLP-1-A26-1 animal study commenced dosing on June 10 with Sprague-Dawley rats. Eleven arms will assess novel DehydraTECH-semaglutide and DehydraTECH-CBD formulations, tracking blood levels at 8–24 hours and measuring brain concentrations to compare pharmacokinetic performance against existing reference formulations.
Lexaria has filed three new patent applications targeting its innovative GLP-1 delivery formulations designed as potential alternatives to SNAC, the absorption enhancer used in leading oral GLP-1 therapies. These filings aim to establish proprietary IP within the competitive GLP-1 segment and support future licensing opportunities.
On June 11, Lexaria secured Australian patent #2023302884 in its Pharmaceutical Compositions and Methods for Treating Hypertension family. This marks the seventh grant in this family and extends protection for its DehydraTECH platform until April 25, 2043, bolstering its global IP portfolio.
